CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1548 participants.
Also called NCT05508256
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,548 participants
- Sponsor
- Registry
-
NCT05508256
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany
- Registry status
- Recruiting
Technical summary
Registry record NCT05508256. Randomized; no masking; primary purpose treatment. Start 2023-03 (anticipated); primary completion 2026-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
- Acronym
- CABA-HFPEF
- Condition
- Atrial Fibrillation
- Condition
- Heart Failure With Mildly Reduced Ejection Fraction
- Intervention (Device)
- CE-marked Catheter Ablation
- Lead sponsor
- Charite University, Berlin, Germany
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator
- Kompetenznetz Vorhofflimmern e.V. (AFNET)
- Collaborator
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct05508256- Content hash
17ba17bead8cabd12382b712c3024095c95bd5ad64904f614380aa5e3a3f8de4